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Abstract: A common characteristic of many cancer cells is that they suffer from oxidative stress.
They, therefore, require effective redox regulatory systems to combat the higher levels of reactive
oxygen species that accompany accelerated growth compared to the normal cells of origin. An
elevated dependence on these systems in cancers suggests that targeting these systems may provide
an avenue for retarding the malignancy process. Herein, we examined the redox regulatory systems
in human liver and lung cancers by comparing human lung adenocarcinoma and liver carcinoma to
their respective surrounding normal tissues. Significant differences were found in the two major
redox systems, the thioredoxin and glutathione systems. Thioredoxin reductase 1 levels were
elevated in both malignancies, but thioredoxin was highly upregulated in lung tumor and only
slightly upregulated in liver tumor, while peroxiredoxin 1 was highly elevated in lung tumor, but
downregulated in liver tumor. There were also major differences within the glutathione system
between the malignancies and their normal tissues. The data suggest a greater dependence of liver
on either the thioredoxin or glutathione system to drive the malignancy, while lung cancer appeared
to depend primarily on the thioredoxin system.
Keywords: antioxidant systems; thioredoxin reductase 1; thioredoxin 1; glutathione;
glutathione peroxidase
1. Introduction
Cancer cells are characterized by hallmarks that set them apart from normal cells, and one of
these hallmarks is uncontrolled cell growth [1]. Cancer cells must depend on strong antioxidant
systems to combat the burdens of oxidative stress generated by elevated levels of reactive oxygen
species (ROS) accompanying unrestrained malignant growth and serving as both “Savior and Satan”
to cell augmentation (e.g., see [2–9] and references therein). Two of the major redox regulatory
systems in mammals that support increased tumor growth are the thioredoxin (TXN) and the
glutathione (GSH) systems [10–20]. The principal functions of these systems are to maintain redox
homeostasis at the level of protein-based and low molecular weight thiols, and both systems are
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comprised of several selenium-containing enzymes (selenoproteins) whose expression levels are
influenced by levels of selenium in the diet. Cancer cells, however, often become increasingly
dependent on these systems as well as on other antioxidants in dealing with excessive oxidative
damage [10–20]. In recent years, one of the primary foci regarding the forces driving cancer
growth has been the disrupted redox homeostasis that accompanies rapid growth. Most certainly,
antioxidants used by cancer cells vary among different cancers suggesting different avenues of
therapy [10–20].
The available evidence suggests that lung adenocarcinoma (non-small cell) and hepatocellular
carcinoma and the corresponding cancer cells utilize antioxidant systems differently to sustain
their malignancies [10–12,16,21–23]. Furthermore, in liver cancer, the incidence of malignancy
in mice maintained on a selenium adequate diet and carrying liver cancer driver transgenes
(TGFα/c-myc) [24], or in mice exposed to the liver carcinogen, diethylnitrosamine (DEN) [25], was
enhanced compared to mice maintained on a selenium deficient or a highly enriched selenium
diet. The latter studies suggested that mouse diets which are selenium deficient or supplemented
with high levels of selenium (2.0 ppm selenium) provide the animals with greater protection from
hepatocarcinogenesis than diets with adequate levels of selenium (0.1 ppm selenium). The role of
varying selenium levels in preventing and promoting cancer has been reviewed recently providing
further examples of selenium deficiency and dietary selenium supplementation in these processes
(see reviews in [26–29]).
Mice lacking the selenoprotein thioredoxin reductase 1 (TXNRD1) in liver manifested a
dramatically higher incidence of tumor development than control mice expressing TXNRD1 when
both mouse lines were treated with a liver carcinogen, DEN [30]. Tumors from the TXNRD1-deficient
mice exhibited upregulated expression of enzymes involved in the GSH system and elevated
levels of another selenoprotein, glutathione peroxidase 2 (GPX2), as well as an enrichment of
additional nuclear factor (erythroid-derived 2)-like 2 (NRF2)-regulated enzymes. These increases
in NRF2-regulated enzymes likely compensated for the oxidative burden of TXNRD1-deficient
hepatoma cells once tumor formation occurred (see also [31–35]). Lung epithelial cells, on the
other hand, appear to utilize selenoproteins and selenium in a different manner than hepatocytes
in protecting lung from oxidative stress and disease. The targeted removal of TXNRD1 in a mouse
lung cancer cell line, LLC1 cells, resulted in the cells reversing many of their malignant properties to
those more similar to normal cells, including a dramatic reduction in tumorigenic and metastatic
properties [36]. The data suggested that the reduction in TXNRD1 levels in lung cancer cells is
anti-tumorigenic. TXNRD1-deficient A549 human lung cancer cells, however, were found to have
only minor changes in growth properties compared to control TXNRD1-sufficient cells, but no other
apparent phenotypic alterations [37]. Even though the knockdown of TXNRD1 in these cells was
almost 90%, the authors concluded that sufficient amounts of this enzyme remained to keep TXN
in the reduced state. Interestingly, A549 TXNRD1-deficient cells were highly sensitive to the drugs,
1-chloro-2,4-dinitrobenzene and menadione, but not to auranofin and juglone, compared to control
cells, suggesting roles of this selenoenzyme independent of TXN [37].
Furthermore, the serum selenium levels were examined in 3333 males over a 16 year period
to assess whether low selenium levels were associated with increased lung cancer incidence [38].
Although low levels of serum selenium levels were not found to be involved with increased
lung cancer risk, a significantly greater risk from lung cancer mortality was observed among
heavy smokers with high serum selenium levels suggesting that higher selenium levels may drive
malignancy. Other studies have reported that low selenium levels may be associated with lung
cancer [39,40], while one of these studies cautioned against the use of selenium as a strategy to prevent
lung cancer [39]. A human clinical trial involving the recurrence of non-small cell lung cancer in
patients given a placebo or selenium supplementation showed no difference between the two groups
resulting in early termination of the trial [41]. Interestingly, a recent study has shown that the time
required for lung tumorigenesis development was reduced and the resulting tumor size increased
2263
Cancers 2015, 7, 2262–2276
dramatically by adding vitamin E or N-acetylcysteine to the diet of mice carrying a lung cancer driver
gene compared to untreated control mice carrying the same cancer driver gene [21].
GSH is an abundant intracellular tripeptide with many biological roles, including protection
against reactive oxygen species (ROS). The GSH system consists of enzymes involved in GSH
synthesis, glutamate-cysteine ligase (GCLC) and glutathione synthetase (GSS), as well as glutathione
peroxidases, glutaredoxins, and glutathione S-transferases. Furthermore, GSH is involved in a
number of vital cell processes such as maintenance of the redox state, detoxification of xenobiotics
and endogenous compounds, and DNA synthesis [20,42–45], including cross-talk between the GSH
and TXN systems [12,16]. Additionally, GSH levels, as well as other components of the GSH system,
have been shown to be elevated in many human cancers [46].
The above studies suggest that lung and liver tumors have altered their antioxidant systems
and/or proteins to support their malignancies. To elucidate the antioxidants and redox regulators
used by human liver and lung cancers, we examined them in greater detail in these two cancers.
2. Results
2.1. Lung and Liver Tumor and Normal Tissues
We examined lung adenocarcinomas (Table 1) and hepatocellular carcinomas (Table 2) and the
respective surrounding normal tissues from three lung cancer and three liver cancer patients. Each
tissue was closely matched in terms of percent malignant cells within the tumor, tumor grade and
stage, as well as patient sex and age. Patients were free of other known diseases, and normal tissues
surrounding tumors were free of malignancy as determined by histopathological analysis. All lung
adenocarcinomas were non-small cell carcinomas.
Table 1. Lung samples 1.
Sample No. Name Pathological Diagnosis 2 Cancer Cell % Grade Stage Sex Age
1
N1 Normal Adjacent Tissue - - -
M 48T1 Adenocarcinoma 70% 2 IIB
2
N2 Normal Adjacent Tissue - - -
M 56T2 Adenocarcinoma 70% 2 IIB
3
N3 Normal Adjacent Tissue - - -
M 59T3 Adenocarcinoma 70% 2 IIB
1 None of the patients had hepatitis B or C, or were HIV positive and all patients were free of other diseases;
2 All lung adenocarcinomas were non-small cell carcinomas.
Table 2. Liver samples 1.
Sample No. Name Pathological Diagnosis Cancer Cell % Grade Stage Sex Age
1
N1 Normal Adjacent Tissue - - -
M 64T1 Hepatocellular Carcinoma 90% 2 II
2
N2 Normal Adjacent Tissue - - -
M 50T2 Hepatocellular Carcinoma 90% 2 II
3
N3 Normal Adjacent Tissue - - -
M 63T3 Hepatocellular Carcinoma 90% 2 II
1 None of the patients had hepatitis B or C, or were HIV positive and all patients were free of other diseases.
2.2. Lung and Liver Tumors Utilize the TXN System Differently
The amounts of three key proteins in the TXN system, TXNRD1, TXN, and peroxiredoxin 1
(PRDX1), in tumor and surrounding normal tissue samples from the three lung and three liver cancer
patients were examined in duplicate by western blotting (Figure 1A–C). All three proteins increased
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significantly in lung tumors compared to normal, surrounding tissues. The tumors from the three
liver cancer patients also manifested a significantly higher increase in TXNRD1 levels (Figure 1B
and lower, right panel in Figure 1C). TXN levels remained fairly constant in liver tumors compared
to normal tissues, while PRDX1 levels decreased. The increases in TXNRD1 were approximately
1.5 fold in lung tumors and approximately 2 fold in liver tumors. It is not clear why liver sample 3
manifested lower levels of PRDX1 in the normal sample compared to the other two normal tissues,
albeit this sample appeared to have slightly enriched amounts of this enzyme compared to the
corresponding cancerous tissue. Further discussion regarding variability of analyzed proteins within
normal samples and within tumor samples is given in Section 2.3.
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Figure 1. Expression of proteins of the TXN system. (A,B) Expression of TXNRD1, TXN and PRDX1 
in normal and tumor lung and liver tissues, respectively, as analyzed by western blotting. N 
designates normal tissue and T, tumor tissue. Coomassie blue staining is shown in the bottom panels 
and used as a control for protein loading; (C) Quantification of band intensities on western blots. 
Relative band intensities of duplicate lanes were quantified as described in the Experimental Section 
and tumor sample (T) values were normalized to the control tissue (N). * Denotes statistical 
differences, p < 0.05; (D) TXNRD catalytic activities in normal and tumor tissues. Activities are 
expressed as µmol of TNB/min/mg of protein for lung (upper panel) and liver tissues (lower panel). 
Values are the means ± S.D. of three independent experiments. Experimental details are given in the 
Experimental Section. 
The TXNRD enzymatic activity was also measured in lung and liver tumor and normal tissues 
(Figure 1D). It was approximately the same in lung tumors, but lower in liver tumors compared to 
normal tissues. The TXNRD activity was 25% higher in normal lung compared to normal liver tissue. 
The differences in the amounts of TXNRD1 protein as assessed by western blotting and TXNRD 
activity, and variations in the three proteins involved in the TXN system in normal and malignant 
tissues between the two organs are further considered below. 
2.3. Lung and Liver Tumors Utilize the GSH System Differently 
The expression of enzymes involved in GSH metabolism, including glutathione reductase (GSR), 
GCLC, GSS, glutaredoxin (GLRX), γ-glutamyltransferase 1 (GGT1), glutathione S-transferase alpha 
1 (GSTA1), and glutathione S-transferase pi 1 (GSTP1), as well as three selenoproteins, glutathione 
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2.3. Lung and Liver Tumors Utilize the GSH System Differently
The expression of enzymes involved in GSH metabolism, including glutathione reductase (GSR),
GCLC, GSS, glutaredoxin (GLRX), γ-glutamyltransferase 1 (GGT1), glutathione S-transferase alpha 1
(GSTA1), and glutathione S-transferase pi 1 (GSTP1), as well as three selenoproteins, glutathione
peroxidase 1 (GPX1), GPX2, and glutathione peroxidase 4 (GPX4), in tumor and surrounding normal
tissue samples from the three lung and three liver cancer patients were examined in duplicate by
western blotting (Figure 2A–C). The levels of GPX1, GPX4, GSR, GSS, and GLRX appeared to increase,
but not significantly, in the three lung tumor samples (Figure 2A and upper panels of Figure 2C),
although GSS in patient 1 and GLRX in patient 2 appeared to increase more dramatically on western
blots than did the corresponding proteins in the other patients. GSTP1 increased significantly in lung
tumor, while GCLC and GGT1 decreased significantly in lung tumor compared to normal tissue.
GSTA1 and GPX2 were not detected in normal lung tissue or the corresponding malignant tissue.
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Figure 2. Expression of proteins of the GSH system. (A,B) Expression of GPX1, GPX2, GPX4, GSR, 
GCLC, GSS, GLRX, GGT1, GSTA1, and GSTP1 in normal and tumor lung and liver tissues, 
respectively, as analyzed by western blotting. GSTA1 and GPX2 were only detected in liver samples 
and therefore not included with the lung samples. N designates normal tissue and T, tumor tissue. 
Coomassie blue staining is shown in the bottom panels and used as a control for protein loading; (C) 
Quantification of band intensities on western blots. Relative band intensities of duplicate lanes were 
quantified as described in the Experimental Section and tumor sample values were normalized to the 
control tissue (N). * Denotes statistical differences, p < 0.05; (D) Glutathione peroxidase activities in 
normal and tumor tissues. Activities are expressed as units/mg of protein for lung (upper panel) and 
liver tissues (lower panel). Values are the means ± S.D. of three independent experiments. 
Experimental details are given in Experimental Section; (E) Amounts of total GSH (GSH + GSSG) in 
lung (upper panel) and liver tissues (lower panel). Total GSH levels are expressed as nmol per mg of 
protein and are the means ± S.D. for three independent experiments. Details are given in the 
Experimental Section. 
Protein concentrations of six of the GSH system enzymes, GPX1, GSR, GCLC, GSS, GLRX, and 
GSTA1, decreased significantly in liver tumors (Figure 2B and lower panels in Figure 2C). GPX4 
increased in tumors, while GGT1 manifested the most dramatic increase. GSTP1 increased 
dramatically in two of the liver tumors, but was unaffected in one of the liver samples. The levels of 
GPX2 and GCLC appeared to decrease in tumors, but not significantly.  
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Figure 2. Expression of proteins of the GSH system. (A,B) Expression of GPX1, GPX2, PX4,
GSR, GCLC, SS, GLRX, GGT1, GSTA1, and GSTP1 in norm l and tumor lung and liver ti sues,
respectively, as analyzed by western blo ting. GSTA1 and GPX2 were only detected in liver samples
and therefore not included with the lung samples. N designates normal ti sue and T, tumor ti sue.
Cooma sie blue staining i shown in the b ttom panels and used as a c ntrol for protein loading;
(C) Quantification of band intensities on western blots. R lative band intensities of duplicate lan s
were quantified as described in the Experim ntal Section and tu or sample values were normalized
to the control tissue (N). * Denotes statistical diff rences, p < 0.05; (D) Glutathione peroxid se activities
in normal and tumor tissues. Activities are expressed as units/mg f protein for l ng (u per pa el)
and liver tissues (lower panel). Values are the means ˘ S.D. of three independent experiments.
Experimental details are given in Experimental Section; (E) Amounts of total GSH (GSH + GSSG)
in lung (upper panel) and liver tissues (lower panel). Total GSH levels are expressed as nmol per
mg of protein and are the means ˘ S.D. for three independent experiments. Details are given in the
Experimental Section.
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Protein concentrations of six of the GSH system enzymes, GPX1, GSR, GCLC, GSS, GLRX,
and GSTA1, decreased significantly in liver tumors (Figure 2B and lower panels in Figure 2C).
GPX4 increased in tumors, while GGT1 manifested the most dramatic increase. GSTP1 increased
dramatically in two of the liver tumors, but was unaffected in one of the liver samples. The levels of
GPX2 and GCLC appeared to decrease in tumors, but not significantly.
While variability among liver samples within normal and within malignant tissues (e.g., GPX2,
GSR, GSS, and GSTP1) and among lung samples within normal and within malignant tissues (GSS,
GLRX (Figure 2) and G6PD (Figure 3) below) may be attributed to the low number of sample sizes,
we raise the possibility that each of the tumors may also be in slightly different transition stages in
developing their dependency on specific enzymes to support the cancer.
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Figure 3. Expression of SOD1, CAT and G6PD. (A,B) Expression of SOD1, CAT and G6PD in normal 
and tumor lung and liver tissues as analyzed by western blotting. N designates normal tissue and T, 
tumor tissue. Coomassie blue staining is shown in the bottom panels and used as a control for protein 
loading; (C) Quantification of band intensities on western blots. Relative band intensities of duplicate 
lanes were quantified as described in the Experimental Section and tumor sample (T) values were 
normalized to the control tissue (N). * Denotes statistical differences, p < 0.05. 
The GPX activity and the GSH levels were also measured (Figure 2D,E, respectively). The GPX 
activity in the liver was about twice that in the lung, but its activity in tumors compared to normal 
tissues was similar (Figure 2D). The levels of GSH in lung tumor and the corresponding normal tissue 
were similar, but normal liver tissue had about twice the amount of GSH than lung; and the level of 
GSH in liver tumor was reduced significantly compared to normal tissue (Figure 2E). 
2.4. Utilization of Other Antioxidant Proteins and Compounds in Lung and Liver Tumor and Normal 
Tissues 
Expression of additional antioxidant proteins, superoxide dismutase 1 (SOD1), catalase (CAT), 
and glucose-6-phosphate dehydrogenase (G6PD), were also examined in lung and liver tumor and 
normal tissues by western blotting (Figure 3). SOD1 appeared to increase slightly and CAT to 
decrease, but not significantly, in lung tumor, while G6PD increased several fold (Figure 3A and 
upper panels of Figure 3C). Liver tumor tissues manifested significant decreases in SOD1 and CAT 
and, like lung, a highly significant increase in G6PD (Figure 3A and lower panels of Figure 3C). 
The levels of two compounds which are considered to be antioxidants, ascorbic acid and uric 
acid, were also measured in the tumor and normal tissues (Figure 4). In normal liver tissues, the 
Figure 3. Expression of SOD1, CAT and G6PD. (A,B) Expression of SOD1, CAT and G6PD in normal
and tumor lung and liver tissues as analyzed by western blotting. N designates normal tissue and T,
tumor tissue. Coomassie blue staining is shown in the bottom panels and used as a control for protein
loading; (C) Quantification of band intensities on western blots. Relative band intensities of duplicate
lanes were quantified as described in the Experimental Section and tumor sample (T) values were
normalized to the control tissue (N). * Denotes statistical differences, p < 0.05.
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2.4. Utilization of Other Antioxidant Proteins and Compounds in Lung and Liver Tumor and Normal Tissues
Expression of additional antioxidant proteins, superoxide dismutase 1 (SOD1), catalase (CAT),
and glucose-6-phosphate dehydrogenase (G6PD), were also examined in lung and liver tumor and
normal tissues by western blotting (Figure 3). SOD1 appeared to increase slightly and CAT to
2267
Cancers 2015, 7, 2262–2276
decrease, but not significantly, in lung tumor, while G6PD increased several fold (Figure 3A and
upper panels of Figure 3C). Liver tumor tissues manifested significant decreases in SOD1 and CAT
and, like lung, a highly significant increase in G6PD (Figure 3A and lower panels of Figure 3C).
The levels of two compounds which are considered to be antioxidants, ascorbic acid and uric
acid, were also measured in the tumor and normal tissues (Figure 4). In normal liver tissues, the
amounts of the compounds were about twice those in normal lung tissues. The amounts of these two
antioxidants in each normal and tumor tissue were similar with the exception of uric acid in liver
which was significantly lower in tumor than normal liver tissue.
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Figure 4. Concentrations of ascorbic acid and uric acid. (A,B) Amounts of ascorbic acid and uric acid, 
respectively, in lung (upper panel) and liver tissues (lower panel). The concentration of ascorbic acid 
and uric acid are expressed as nmol per mg of protein and are the means ± S.D. for three independent 
experiments. * Denotes statistical difference, p < 0.05. Experimental details are given in the 
Experimental Section. 
3. Discussion 
TXNRD1 is one of key redox regulators in mammalian cells [16,47–50], and therefore helps 
protect both normal and cancer cells from oxidative stress. It appears to serve a protective function 
in healthy cells, and to have a tumor-promoting function when cells have transformed. It is elevated 
in many tumors and cancer cells, which led numerous investigators to propose this selenoenzyme as 
a target for cancer therapy [16,17,36,51–55]. However, prior to undertaking human clinical trials 
involving the inhibition of TXNRD1, much more understanding of the dependence of the targeted 
tissue on a specific antioxidant system (or systems) and the interplay between different antioxidants, 
antioxidant systems, and antioxidant regulatory proteins [2,3,6,8,9,15,56–58] are warranted. The 
consequences of targeting a single protein, such as TXNRD1, would most likely be the induction of 
NRF2, at least in some tissues [30,31,59]. NRF2 has been reported to be a transcription factor having 
important roles in maintaining redox balance and protecting cells from electrophilic stress (see 
[33,56,60] and references therein). Downregulation of NRF2 in carcinogen treated mice was reported 
to result in elevated tumor incidence suggesting greater susceptibility to malignancy (see [61,62] and 
references therein). However, in lung cancer, NRF2-deficient mice treated with the lung carcinogen, 
urethane, were reported to initially manifest an increase in tumor formation, whereas the 
corresponding NRF2-sufficient, chemically treated mice developed more tumors at later stages with 
a higher number of K-RAS-mutated adenocarcinomas [35]. These investigators suggested that the 
Figure 4. Concentrations of ascorbic acid and uric acid. (A,B) Amounts of ascorbic acid and uric
acid, respectively, in lung (upper panel) and liver tissues (lower panel). The concentration of ascorbic
acid and uric acid are expressed as nmol per mg of protein and are the means ˘ S.D. for three
independent experiments. * Denotes statistical difference, p < 0.05. Experimental details are given
in the Experimental Section.
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having important roles in maintaining redox balance and protecting cells from electrophilic stress
(see [33,56,60] and references therein). Downregulation of NRF2 in carcinogen treated mice was
reported to result in elevated tumor incidence suggesting greater susceptibility to malignancy
(see [61,62] and references therein). However, in lung cancer, NRF2-deficient mice treated with
the lung carcinogen, urethane, were reported to initially manifest an increase in tumor formation,
whereas the corresponding NRF2-sufficient, chemically treated mice developed more tumors at later
stages with a higher number of K-RAS-mutated adenocarcinomas [35]. These investigators suggested
that the data revealed two roles of NRF2 during cancer development: (1) a preventive role during
tumor initiation and (2) a promotion role in malignant progression.
The current study underscores the importance of elucidating the interplay between different
antioxidant proteins and systems. As noted in the Introduction, the available evidence
suggests that lung and liver cancers differ in how they utilize antioxidant systems to sustain
malignancies [10–12,16,21–23]. Herein, we examined the two major antioxidant systems in mammals,
the TXN and GSH systems, and several other known antioxidants in lung and liver tumors compared
to their respective surrounding normal tissues to assess how these components changed in response
to the burden of oxidative stress and enhanced growth rates. We also assessed how the tumors
in these two tissues differ in utilizing these antioxidants. With regard to the TXN system, the
relative amounts of TXN and PRDX1 were almost four times higher in lung tumors compared to
the corresponding normal tissues, while TXN levels were approximately equal in liver tumor and
normal tissues; and the levels of PRDX1 were reduced more than 50%. In addition, although lung had
approximately 1.5X greater TXNRD activity in normal tissue compared to the corresponding tissue in
liver, the tumor and normal tissues had similar activities in both organs. These data suggest that lung
tumor and possibly the surrounding normal tissue have a greater dependence on the TXN system to
protect the respective tissues from oxidative stress than liver tumor and surrounding normal tissue.
Western blot analysis revealed higher TXNRD1 levels were present in tumors compared to
the respective surrounding normal tissues in both lung and liver, but, as noted above, activity
assessments showed similar TXNRD activities. This observation suggested that replacement of the
Sec residue with another amino acid, or truncation of TXNRD1 occurred in the malignant tissues.
Unfortunately, we were not able to obtain sufficient tissue from the patients used herein to determine
the amino acid replacement of the Sec residue and/or truncation of TXNRD1 to assess the influence
of these parameters on TXNRD1 function, and concomitantly, on the malignancy process.
The levels of several enzymes in the GSH system and the total amount of GSH were also assessed
in the various tissues. The enzymes included two selenoenzymes, GPX1 and GPX4, and several
other proteins, GSR, GCLC, GSS, GLRX, GGT1, GSTA1, and GSTP1. Although the levels of several
of these proteins, GPX1, GPX4, GSR, GSS, and GLRX, appeared to increase slightly in lung tumor
samples compared to corresponding normal tissue, two of the proteins, GCLC and GGT1, decreased
significantly in the tumors. GSTA1 was not detectable in lung tissue, however, GSTP1 increased
significantly in lung tumors, indicating that GSTP1 may play a role in detoxification and maintenance
of lung cancer cells. The GST family of enzymes, which uses GSH to detoxify a wide variety of
molecules, are involved in kinase-mediated signaling pathways and their presence in tumors can
contribute to drug resistance [42,45]. GSTP1 is widely distributed and has previously been shown
to be increased in many cancer types and is the most predominantly expressed GST isozyme in the
NCI-60 cancer cell line panel [45]. On the other hand, the GSH metabolic enzymes, GPX1, GSR, GCLC,
GSS, GLRX, and GSTA1, were found to be downregulated in liver tumors compared to normal tissues,
while GPX4 and GGT1 showed significant increases. GPX specific activities in liver were about twice
those in lung, although both normal and malignant tissues had similar activities in the two organs.
The total amount of GSH in lung tumor and the corresponding normal tissue was similar and about
half that observed in normal liver, but normal liver tissue had three times the amount of GSH than
the corresponding tumor. A large decrease in GSH levels was observed in liver within tumor tissue,
while GPX activity did not increase. However, GSH levels and the GPX activity do not necessarily
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correlate. The activity assay determines the capacity to reduce H2O2, but within cells, activity levels
are influenced by the availability of reducing equivalents for this reaction, as well as the interplay
with other processes. The decrease observed in liver tumors is likely due to the decreased activity of
the GSH-synthesizing enzymes, GCLC and GSS, and may also reflect an increased utilization of GSH
in the tumors. GSTP1 levels were increased in two of the three liver tumor samples examined. The
apparent upregulation of GSTP1 in some liver tumors may be compensatory and due, in part, to a
decrease in GSTA1 in these tumors.
The changes in levels of antioxidant proteins and other antioxidants examined in lung and
liver tumors compared to surrounding normal tissues are summarized in Table 3. These findings
illustrate the differences in how these two tumors depend on antioxidants to drive the respective
malignancy. One protein that was highly upregulated in lung and liver tumors was G6PD. G6PD is
the rate-limiting enzyme of the pentose phosphate pathway, reducing NADP+ to NADPH, which is
required for the reduction of GSH and TXN, lipid and DNA synthesis, and for certain detoxification
reactions [63]. Thus, it plays a critical role in antioxidant defense, generating ribose-5-phosphate for
the biosynthesis of nucleotides, and supporting other cellular functions, but its specific role in the
overall malignancy process is not completely understood [64]. Recently discovered roles of G6PD
in angiogenesis, cellular proliferation, and resistance to cancer therapy suggest that this protein is
likely a major factor in the malignancy process [63,64]. Its highly enriched levels in the two cancers
examined herein suggests that it may play a role in combating the increased oxidative stress that
accompanies the respective malignancy and this observation warrants further study. SOD1 and
CAT function in the reduction of superoxide to hydrogen peroxide and the conversion of hydrogen
peroxide to water and oxygen, respectively [65,66]. SOD1 and CAT were not significantly altered in
lung tumors, yet both were significantly reduced in liver tumors. Alterations in both SOD1 and CAT
have been implicated in cancer, most likely due to their roles in modulating ROS levels [65,66]. For
example, mice deficient in SOD1 have been shown to develop hepatocellular carcinomas [67].
Table 3. Summary of changes in levels of redox components examined in tumor and normal
surrounding tissues 1.
Antioxidant Lung 2 Liver 2
TXNRD1 Ò Ò
TXN Ò NS
PRDX1 Ò Ó
GPX1 NS Ó
GPX2 ND NS
GPX4 NS Ò
GSR NS Ó
GCLC Ó Ó
GSS NS Ó
GLRX NS Ó
GGT1 Ó Ò
GSTA1 ND Ó
GSTP1 Ò NS
SOD1 NS Ó
CAT NS Ó
G6PD Ò Ò
Ascorbic acid NS NS
Uric acid NS Ó
1 The observations in the table are based on quantitation of western blot analysis; 2 Ò or Ó arrows indicate
significant increase (Ò) or decrease (Ó); NS = not significant; ND = not detected.
Several studies have shown how the interplay of different antioxidants and other redox
regulators influence the malignancy process. Conrad and collaborators [18] were the first to show that
malignant transformed mouse cells (mouse embryonic, fibroblast cells) required both an inhibition of
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TXNRD1 and the GSH system to retard the malignancy and generate a cell line more like the original,
normal cells. A synergistic effect between GSH initiating cancer development and TXN promoting
cancer development both in vitro and in vivo has been reported, wherein the inhibition of both systems
led to cancer cell death [12]. A recent report has shown a surprising example of the interrelationship
between different antioxidant proteins in mouse colon cancer cells, wherein the downregulation of
either the 15kDa selenoprotein or TXNRD1 resulted in the reversal of several malignant properties
to those more like normal cells; however, the double knockdown of both proteins reversed the
anti-malignant properties rendering the cells with additional cancer properties [68]. Interestingly,
GPX4 has been shown to have a major role in ferroptotic cancer cell death [69,70] showing that this
selenoprotein also plays a role in the malignancy process. Furthermore, adequate selenium in the diet
has long been correlated with cancer prevention [71], but a recent study reported that mice encoding
genetically induced lung cancer and administered vitamin E and N-acetylcholine developed tumors
much more readily and died much earlier than control mice [21]. This study also found that the two
dietary antioxidants enhanced tumor growth by disrupting the association between p53 and ROS.
The present study and those discussed above strongly suggest that much more insight into
the dependence of specific tissues on various antioxidants is required before undertaking human
clinical trials targeting the removal of specific antioxidants or antioxidant systems. Clearly, as shown
herein, there are major differences in normal and tumor tissues from lung and liver in how they
utilize antioxidants to maintain a careful redox balance in normal cells and how these antioxidants
are enriched and new ones induced in tumors to drive the malignancy. The observations that
lung, non-small cell adenocarcinomas have highly enriched levels of TXN and PRDX1 (see Table 3),
suggest that these two components provide major antioxidant support in combating the oxidative
stress accompanying this specific carcinoma in lung. PRDX1 protects against oxidative stress by
removing hydrogen peroxide, peroxynitrite and organic hydroperoxides, and is known to be reduced
by TXN [16], supporting the proposal that non-small cell carcinoma in lung utilizes increased TXN
to maintain PRDX1 in the reduced, active state. Our findings also indicate that an examination of
the inhibition of TXN and/or PRDX1 as potential targets to diminish this malignancy are worthy of
further consideration.
4. Experimental Section
4.1. Tissues and Other Materials
Human lung adenocarcinoma and hepatocellular carcinoma and surrounding normal tissues
were purchased from ILSbio. Descriptions of these tissues and other pertinent information are given
in Table 1 (lung) and Table 2 (liver).
Primary antibodies for detecting TXNRD1, GPX4, and GSR were purchased from Epitomics
(Burlingame, CA, USA), for detecting GPX1, GCLC, GSS, TXN, and SOD1 from Abcam (Cambridge,
MA, USA), for GPX2, GSTA1, and GSTP1 from Detroit R&D (Detroit, MI USA), for Histone H3
from Millipore (Billerica, MA, USA), for GGT1 from GeneTex (Irvine, CA, USA), for GLRX from
Sigma-Aldrich (St. Louis, MO, USA), for CAT from AbFrontier (Seoul, Korea) and for G6PD and
PRDX1 from Cell Signaling Technology (Danvers, MA, USA). Anti-rabbit HRP-conjugated secondary
antibody was from Cell Signaling Technology. Anti-goat HRP-conjugated secondary antibody
was from Sigma-Aldrich. Coomassie Blue staining solution, β-nicotinamide adenine dinucleotide
phosphate reduced tetrasodium salt (NADPH), 5,51-dithiobis (2-nitrobenzoic acid) (DNTB) and
glutathione assay kit were obtained from Sigma-Aldrich and complete mini protease inhibitor
cocktail from Roche (Indianapolis, IN, USA). BCA protein assay reagent, SuperSignal West Dura
Extended Duration Substrate, PVDF membrane and NuPage 4%–12% Bis-Tris gels were purchased
from Thermo Fisher Scientific Inc (Grand Island, NY, USA), Glutathione peroxidase activity kit was
obtained from Enzo Life Science (Farmingdale, NY, USA), ascorbic acid assay kit from BioAssay
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System (Hayward, CA, USA) and uric acid assay kit from Thermo Fisher Scientific (Grand Island,
NY, USA).
4.2. Tissue Preparation, Protein Concentration, and Western Blotting
Tissues were homogenized in phosphate buffered saline (PBS) with 0.5% (v/v) Triton X-100
and complete protease inhibitor cocktail, and protein amounts measured using BCA protein assay
reagent. Thirty µgs of each protein sample were electrophoresed on NuPAGE Bis-Tris gels,
transferred to a PVDF membrane, and then incubated initially with each primary antibody and
finally with HRP-conjugated secondary antibody. Membranes were treated with SuperSignal West
Dura Extended Duration Substrate and exposed to X-ray film. Following western blot analyses,
membranes were stained with Coomassie Blue staining solution to evaluate protein loading and serve
as a loading control. This was the preferred technique for assessing protein levels due to the large
variability in expression of loading controls such as GAPDH, β-Actin and α-Tubulin [72–76]. We
found that neither GAPDH, β-Actin, nor α-Tubulin would serve as loading controls due to their large
variations in normal and malignant tissues (data not shown). The band intensities on western blots
were quantified and normalized to total protein staining using ImageJ software (National Institutes
of Health, Bethesda, MD, USA).
4.3. Enzyme Activity Assay
TXNRD activities were determined in protein extracts, which were prepared as described above,
by mixing the extracts with 100 mM potassium phosphate (pH 7.0), 10 mM EDTA, 0.24 mM NADPH
and 3 mM DTNB and the reduction of DTNB by TXNRD measured by absorbance at 412 nm
spectrophotometrically (34). GPX activities were determined in protein extracts using a GPX activity
kit (Enzo Life Science) according to the manufacturer’s instructions. The proteins were quantified
with BCA protein assay reagent.
4.4. Determination of Total Glutathione, Ascorbic Acid, and Uric Acid Concentrations
The concentration of total glutathione (GSH + GSSG), ascorbic acid and uric acid in tumor
and normal tissues were determined using the respective assay kits according to the manufacturer’s
instructions. The proteins were quantified with BCA protein assay reagent.
4.5. Statistical Analysis
Values in all figures are presented as the standard error of the mean (SEM). Statistical analyses
were performed using Student’s t-test with GraphPad Prism software (Version 5, La Jolla, CA, USA).
The level of significance was set at p = 0.05.
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